Summers KM, Kockler DR. Rituximab treatment of refractory rheumatoid arthritis. Ann Pharmacother. 2005;39:2091–5. https://doi.org/10.1345/aph.1G311.
Article PubMed CAS Google Scholar
KDIGO. Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;2024(105):S1-69. https://doi.org/10.1016/j.kint.2023.09.002.
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45. https://doi.org/10.1136/annrheumdis-2019-215089.
Article PubMed CAS Google Scholar
Chen P, Zhou Y, Wu L, Chen S, Han F. Efficacy and safety of biologic agents for lupus nephritis: a systematic review and meta-analysis. J Clin Rheumatol. 2023;29:95–100. https://doi.org/10.1097/RHU.0000000000001877.
KDIGO 2024 Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5:22–33. https://doi.org/10.4161/mabs.22771.
Article PubMed PubMed Central Google Scholar
Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. B cell trophic factors and B cell antagonism in autoimmune disease. 8. 2005.
Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118:358–67. https://doi.org/10.1182/blood-2010-09-305847.
Article PubMed CAS Google Scholar
Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? Blood. 2017;130:581–9. https://doi.org/10.1182/blood-2017-03-771832.
Article PubMed CAS Google Scholar
Smith KGC, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10:328–43. https://doi.org/10.1038/nri2762.
Article PubMed CAS PubMed Central Google Scholar
Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118:2530–40. https://doi.org/10.1182/blood-2011-01-330357.
Schieber T, Li A, Lundberg J, Wiczer T, Voorhees T. Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders. Blood Adv. 2023;7:3431–4. https://doi.org/10.1182/bloodadvances.2022009548.
Article PubMed CAS PubMed Central Google Scholar
Teeling JL, Mackus WJM, Wiegman LJJM, Van Den Brakel JHN, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 1. pp. 177. 2006.
Beers SA, French RR, Chan HTC, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191–201. https://doi.org/10.1182/blood-2010-01-263533.
Article PubMed CAS Google Scholar
Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009;46:2419–23. https://doi.org/10.1016/j.molimm.2009.04.009.
Article PubMed CAS Google Scholar
Johnson NA, Leach S, Woolcock B, Deleeuw RJ, Bashashati A, Sehn LH, et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica. 2009;94(3):423–7. https://doi.org/10.3324/haematol.2008.001024.
Article PubMed CAS PubMed Central Google Scholar
Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003. https://doi.org/10.1182/blood-2002.
Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738–43. https://doi.org/10.1182/blood-2003-06-2031.
Article PubMed CAS Google Scholar
Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, et al. Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions. J Immunol. 2016;197:1762–75. https://doi.org/10.4049/jimmunol.1600648.
Article PubMed CAS PubMed Central Google Scholar
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell - mediated B-cell cytotoxicity. Blood. 2010;115:4393–402. https://doi.org/10.1182/blood-2009-06-225979.
Article PubMed CAS PubMed Central Google Scholar
Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117:4519–29. https://doi.org/10.1182/blood-2010-07-296913.
Article PubMed CAS PubMed Central Google Scholar
Illidge TM, Cheadle EJ, Honeychurch J. New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor. Leuk Lymphoma. 2014;55:3–4. https://doi.org/10.3109/10428194.2013.797976.
Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367:1224–30. https://doi.org/10.1126/science.aaz9356.
Article PubMed CAS Google Scholar
Kumar A, Planchais C, Fronzes R, Mouquet H, Reyes N. Binding mechanisms of therapeutic antibodies to human CD20 Downloaded from. 2020.
Gagez AL, Cartron G. Obinutuzumab: A new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 2014;26:484–91. https://doi.org/10.1097/CCO.0000000000000107.
Article PubMed CAS Google Scholar
Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. Baff mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000. https://doi.org/10.1084/jem.192.10.1453.
Article PubMed PubMed Central Google Scholar
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood. 2002. https://doi.org/10.1182/blood.V99.3.754.
Könitzer JD, Sieron A, Wacker A, Enenkel B. Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0145633.
Article PubMed PubMed Central Google Scholar
Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49:1012–24. https://doi.org/10.1177/0091270009337512.
Article PubMed CAS Google Scholar
Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182:29–45. https://doi.org/10.1111/bjh.15232.
Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. J Am Soc Nephrol. 2021;32:2652–63. https://doi.org/10.1681/ASN.2021040561.
Comments (0)